JPMorgan stock set for earnings test as Trump floats 10% credit-card rate cap
11 January 2026
2 mins read

JPMorgan stock set for earnings test as Trump floats 10% credit-card rate cap

New York, Jan 11, 2026, 10:15 EST — The market has closed.

  • JPMorgan shares slipped modestly on Friday as the market braces for a busy week of data releases and earnings reports from banks
  • The White House’s fresh effort to cap credit-card rates has landed card issuers on watchlists
  • On the same day, investors will see U.S. inflation figures alongside the first major bank earnings reports

Shares of JPMorgan Chase & Co (JPM.N) slipped 0.2% to close at $329.19 on Friday, setting a subdued tone ahead of what might be a turbulent week for the largest U.S. bank.

The bank kicks off big-bank earnings on Tuesday, with investors also eyeing the U.S. Consumer Price Index report for December—a key number that could shift expectations around Federal Reserve rate cuts. Later in the week, Citigroup, Bank of America, and Goldman Sachs will report results. Analysts expect financial-sector earnings to rise roughly 7% in the fourth quarter compared to a year ago. “The banks are … on the front lines,” said Jack Janasiewicz, portfolio manager at Natixis Investment Managers, highlighting credit and consumer trends as a critical indicator. (Reuters)

Late Friday brought a new twist in policy. President Donald Trump proposed capping credit-card interest rates at 10% for one year, aiming for the rule to take effect by Jan. 20, though he offered little on the mechanics. “We will no longer let the American public be ripped off,” Trump declared. Banking groups, however, warned such a cap might reduce credit access and drive borrowers to riskier, higher-cost lenders. (AP News)

JPMorgan treads carefully when it comes to cap talk: credit cards drive high yields and serve as a key indicator of household stress. Investors often view the bank’s initial earnings report as an early gauge of delinquencies, loss reserves, and the overall health of consumers—before focusing on trading and deal figures.

JPMorgan’s investment banking unit is highlighting a beefier pipeline. Anu Aiyengar, the bank’s global head of advisory and M&A, told Reuters that the “level of shocks … are very broad.” She added that larger companies have more tools to manage rising volatility. Drawing on LSEG data, Aiyengar noted 2025 M&A activity is projected at $5.1 trillion, with a record 68 deals topping $10 billion last year. (Reuters)

Investors tuning in to JPM’s report will zero in on net interest income — basically the gap between earnings from loans and securities versus what the bank pays on deposits and funding — as falling policy rates start to impact pricing. Attention will also turn to the provision for credit losses, the reserves for potentially bad loans, while any changes in credit-card and consumer banking trends will be scrutinized closely.

Traders are set to focus on the bank’s remarks about costs and staffing. JPMorgan has poured significant funds into technology and compliance lately, so any sign that expense growth is slowing down—or picking up again—could sway the stock just as much as beating earnings estimates.

But the setup cuts both ways. A hotter-than-expected CPI reading might shake up rate expectations and the yield curve—the spread between short- and long-term interest rates that often steers bank profits. Policy announcements on credit cards could spark a prolonged battle, forcing investors to guess the fallout amid sketchy details.

As markets reopen Monday, investors will zero in on early shifts in bank stocks and Treasury yields. These moves could hint at positioning ahead of Tuesday’s packed slate, featuring inflation data and JPMorgan’s earnings release.

JPMorgan announced it will report its fourth-quarter and full-year 2025 results around 7:00 a.m. ET on Tuesday, followed by an earnings call at 8:30 a.m. ET. (JPMorgan Chase)

Stock Market Today

  • Profound Medical: Top TSX Growth Stock Poised for Rapid Expansion, Q3 Revenues Surge 87%
    February 1, 2026, 9:22 PM EST. Profound Medical (TSX:PRN), a Canadian medical device firm specializing in MRI-guided ultrasound therapies, is highlighted as the sole TSX growth stock to hold for the next three years. The company reported an 87% revenue increase in Q3 to $5.3 million, driven by expanded installations of its flagship TULSA-PRO prostate cancer treatment system. Offering incision-free, MRI-guided ablation technology, Profound's procedures have gained Medicare approval with rising insurance reimbursements. Despite a net loss of $8 million, the company improved gross margins to 74.3% and ended Q3 with $25 million cash, supporting near-term liquidity. With 70 systems installed and 93 in advanced sales stages, Profound aims for 75 installations by year-end, making it a notable small-cap growth stock in healthcare on the TSX.
Walmart stock set for Nasdaq-100 entry as Google Gemini deal and Wing drones land
Previous Story

Walmart stock set for Nasdaq-100 entry as Google Gemini deal and Wing drones land

ASML stock jumps 7% into the weekend as analysts bet on a 2026 EUV upcycle
Next Story

ASML stock jumps 7% into the weekend as analysts bet on a 2026 EUV upcycle

Go toTop